Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Cytek Biosciences (CTKB) Receivables - Net (2020 - 2026)

Cytek Biosciences filings provide 6 years of Receivables - Net readings, the most recent being $62.5 million for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 3.17% to $62.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $62.5 million, a 3.17% increase, with the full-year FY2025 number at $62.5 million, up 3.17% from a year prior.
  • Receivables - Net hit $62.5 million in Q4 2025 for Cytek Biosciences, up from $56.6 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $62.5 million in Q4 2025 to a low of $24.0 million in Q2 2021.
  • Median Receivables - Net over the past 5 years was $49.6 million (2023), compared with a mean of $46.4 million.
  • Biggest five-year swings in Receivables - Net: surged 75.16% in 2021 and later fell 10.04% in 2024.
  • Cytek Biosciences' Receivables - Net stood at $29.8 million in 2021, then surged by 64.19% to $48.9 million in 2022, then grew by 14.46% to $55.9 million in 2023, then rose by 8.33% to $60.6 million in 2024, then grew by 3.17% to $62.5 million in 2025.
  • The last three reported values for Receivables - Net were $62.5 million (Q4 2025), $56.6 million (Q3 2025), and $56.2 million (Q2 2025) per Business Quant data.